filmov
tv
MCRC
0:01:22
Influence of sidedness on prognosis and treatment in mCRC
0:04:25
MCRC Director's Update May 2024
0:05:02
Third-Line Treatment Options for mCRC
0:05:33
Treatment Options for KRAS-Mutant Unresectable mCRC
0:07:55
Maintenance Therapy for mCRC
0:07:36
Later-Line Therapy Innovations in MCRC
0:02:23
My Chemical Romance - Cancer
0:03:33
Predictive Markers for mCRC
0:00:42
Dr. Mahipal on Molecular Markers in mCRC
0:03:21
Newly Diagnosed mCRC Treatment Goals
0:05:42
FRESCO-2: subgroup analysis of fruquintinib in mCRC with liver metastases
0:04:57
Case 2: Maintenance Therapy in mCRC
0:01:17
Assessing risk of disease progression in first-line mCRC therapy
0:04:36
Diagnosis of mCRC
0:02:40
Future Research and the Clinical Management of mCRC
0:01:06
PANAMA, XELAVIRI & VALENTINO: gene expression signature for risk stratification in mCRC
0:01:43
Areas of Controversy in the Treatment Landscape of mCRC
0:01:28
Dr. Heinemann on Implications of SIRFLOX Study for mCRC
0:01:45
BREAKWATER: encorafenib plus cetuximab in patients with BRAF V600E-mutant mCRC
0:06:11
Future Directions in Later Line Therapy for mCRC
0:07:58
Choices for Upfront Therapy for mCRC
0:03:58
Dr. Cathy Eng on Bevacizumab Plus FOLFOXIRI for Patients With mCRC
0:02:18
Prognosticating BRAF-Mutant mCRC
0:00:57
Analyzing the Importance of Biomarker Testing and MSI Status in mCRC
Вперёд
0:01:22
0:04:25
0:05:02
0:05:33
0:07:55
0:07:36
0:02:23
0:03:33
0:00:42
0:03:21
0:05:42
0:04:57
0:01:17
0:04:36
0:02:40
0:01:06
0:01:43
0:01:28
0:01:45
0:06:11
0:07:58
0:03:58
0:02:18
0:00:57